Evidence map›Paper›PMID 35930229›Full record

ArticleAdvances in experimental medicine and biology2022

Metabolomics: A Powerful Tool to Understand the Schizophrenia Biology.

Flávia da Silva Zandonadi, Emerson Andrade Ferreira Dos Santos, Mariana Silveira Marques, Alessandra Sussulini

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Flávia da Silva ZandonadiLaboratory of Bioanalytics and Integrated Omics (LaBIOmics), Department of Analytical Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Emerson Andrade Ferreira Dos SantosLaboratory of Bioanalytics and Integrated Omics (LaBIOmics), Department of Analytical Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Mariana Silveira MarquesLaboratory of Bioanalytics and Integrated Omics (LaBIOmics), Department of Analytical Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Alessandra SussuliniLaboratory of Bioanalytics and Integrated Omics (LaBIOmics), Department of Analytical Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, SP, Brazil. sussulini@unicamp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

absvtractSchizophrenia, as any other psychiatric disorder, is a multifactorial and complex illness whose etiology is not completely established. Therefore, studies involving strategies that are able to describe the molecular alterations caused by the disease and, consequently, indicate the altered metabolic pathways are of increasing interest. Metabolomics is a very suitable approach that can be applied for this task, since it consists of the evaluation of the set of metabolites contained in a biological system undergoing a biological process, such as a disease or treatment. In metabolomics, state-of-the-art analytical techniques (mass spectrometry and nuclear magnetic resonance) are employed to identify and quantify the metabolites present in the studied biological samples, and chemometric and bioinformatic tools are applied to determine the specific metabolites and metabolic pathways that are relevant to the biological process under investigation. The aim of this chapter is to describe the basic principles of metabolomics, how this strategy can improve the understanding of the schizophrenia biology, and the findings obtained so far.

Indexed as

SchizophreniaHumansMagnetic Resonance SpectroscopyMass SpectrometryMetabolic Networks and PathwaysMetabolomicsBioinformaticsChemometricsMass spectrometryMetabolomicsNuclear magnetic resonanceSchizophrenia

Identifiers

PMID35930229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.